Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination With Temozolomide Against Malignant Gliomas
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-3151
Full Text
Open PDFAbstract
Available in full text
Date
July 5, 2017
Authors
Publisher
American Association for Cancer Research (AACR)